Inventiva (NASDAQ:IVA) Price Target Lowered to $17.00 at Stifel Nicolaus

Inventiva (NASDAQ:IVA) had its target price reduced by Stifel Nicolaus from $20.00 to $17.00 in a research note issued to investors on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other brokerages have also recently weighed in on IVA. HC Wainwright lowered their price target on shares of Inventiva from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday, October 15th. UBS Group initiated coverage on shares of Inventiva in a research note on Tuesday, November 12th. They issued a “neutral” rating and a $3.00 price target for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.25.

Inventiva Stock Performance

NASDAQ:IVA opened at $2.67 on Friday. Inventiva has a 52 week low of $1.53 and a 52 week high of $4.75. The stock’s 50-day moving average price is $2.38 and its 200-day moving average price is $2.64.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Inventiva stock. Virtu Financial LLC bought a new stake in shares of Inventiva S.A. (NASDAQ:IVA) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 10,490 shares of the company’s stock, valued at approximately $38,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.